Cargando…
Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues....
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863640/ https://www.ncbi.nlm.nih.gov/pubmed/29593389 http://dx.doi.org/10.2147/IJN.S124701 |
_version_ | 1783308421896863744 |
---|---|
author | Singh, Sanjay |
author_facet | Singh, Sanjay |
author_sort | Singh, Sanjay |
collection | PubMed |
description | Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. |
format | Online Article Text |
id | pubmed-5863640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58636402018-03-28 Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells Singh, Sanjay Int J Nanomedicine Short Report Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. Dove Medical Press 2018-03-15 /pmc/articles/PMC5863640/ /pubmed/29593389 http://dx.doi.org/10.2147/IJN.S124701 Text en © 2018 Singh. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Short Report Singh, Sanjay Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
title | Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
title_full | Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
title_fullStr | Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
title_full_unstemmed | Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
title_short | Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
title_sort | liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863640/ https://www.ncbi.nlm.nih.gov/pubmed/29593389 http://dx.doi.org/10.2147/IJN.S124701 |
work_keys_str_mv | AT singhsanjay liposomeencapsulationofdoxorubicinandcelecoxibincombinationinhibitsprogressionofhumanskincancercells |